MWNA
ADVM

Marshall Wace North America’s Adverum Biotechnologies ADVM Stock Holding History

Marshall Wace North America’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,738
Closed -$297K – 1469
2020
Q4 		$297K Buy
2,738
+1,436
+110% +$178K ﹤0.01% 1172
2020
Q3 		$134K Buy
+1,302
New +$195K ﹤0.01% 1153
2018
Q4 		– Sell
-37,879
Closed -$2.29M – 1450
2018
Q3 		$2.29M Buy
+37,879
New +$2.13M 0.02% 466

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Marshall Wace North America's ADVM Position: Q1 2021 in Review

Marshall Wace North America sold out of Adverum Biotechnologies (ADVM) in Q1 2021, closing a stake of 2,738 shares — an estimated $297K sold.

Marshall Wace North America first reported a position in ADVM in Q3 2018 and held it in 3 quarters. The position peaked at $2.29M in Q3 2018. 132 funds tracked by Wall St. Rank hold ADVM as of Q1 2021.

  • Marshall Wace North America reported no remaining Adverum Biotechnologies position as of Q1 2021 after selling out during the quarter.
  • Marshall Wace North America sold 2,738 Adverum Biotechnologies shares in Q1 2021, an estimated $297K.
  • Marshall Wace North America first reported a position in Adverum Biotechnologies in Q3 2018 and held it in 3 quarters.
  • Marshall Wace North America's Adverum Biotechnologies position peaked at $2.29M in Q3 2018.
  • 132 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.